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OBJECTIVE: The ASP is one of the most frequent infectious
diseases and represents one of the principal causes of outpatient
services demand in Mexico. The purpose of this study was to
estimate the cost-effectiveness between single-dose azithromycin
microspheres formulation vs. other usual antibiotics in the man-
agement of ASP from the Mexican Health Service perspective.
METHODS: A three-month Bayesian decision tree model was
performed to estimate costs and effectiveness. Effectiveness
measure used was the percentage of clinical success rate (signiﬁ-
cant improvement of symptoms in a period not longer than a
four-day treatment). Comparators employed were single-dose
azithromycin oral suspension (60 ml); amoxicillin (1000 mg/day);
penicillin (600,000 U/day); ampicillin (1500 mg/day); clarithro-
mycin (500 mg/day); erythromycin (1000 mg/day) trimetoprim +
sulfametoxazol and azithromycin (500 mg/day per 3 d). Clinical
efﬁcacy was obtained from international published literature.
Resource use data and costs were obtained from a retrospective
review of hospital records (n = 100) in patients treated at the
Social Security Mexican Institute (IMSS) in Mexico City. The
model was calibrated. One-way sensitivity analysis and probabi-
listic sensitivity analyses were performed. MonteCarlo ﬁrst order
sensitivity analysis was done using bootstrapping techniques.
RESULTS: The patients treated with azithromycin oral-
suspension experienced the highest effectiveness (93%; CI95%
90%–97%), followed for azithromycin (3-days) treatment (79%;
CI95% 77%–81%) and erythromycin (67%, CI95% 66%–
68%). On the other hand, amoxicillin and trimetoprim showed
the less effectiveness compared to the baseline therapy (penicillin
[57%; IC95% 56%–58%]). The mean treatment costs for
azithromycin oral-suspension was US$110.9 (CI95% US$109.3–
US$112.1); US$122.3 (CI95% $1329.10–$1365.56) for
azithromycin (3-days) and US$128.1 (CI95% US$127.0–
US$132.2) with erythromycin. The ICER’s were US$-49.8
(CI95% -US$41.7,-US$60.4) for azithromycin oral-suspension,
-US$30.6 (CI95% -US$20.0,-US$40.4) and -US$25.5 (CI95%
-US$21.9,-US$30.36) for erythromycin. Probabilistic sensitivity
analyses showed that the single-dose azithromycin oral-
suspension was the dominant therapy (p < 0.05). CONCLU-
SION:Despite its higher cost, the study demonstrates that azithro-
mycin oral-suspension treatment, due to its higher compliance
rate, is a dominant therapy in the treatment of ASP in Mexico.
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OBJECTIVE: To evaluate the cost effectiveness and cost utility of
sunitinib compared with interferon-alfa (IFN-alfa) for ﬁrst-line
treatment of patients with Metastatic Renal Cell Carcinoma
(mRCC) from Colombia third-party payer perspective.
METHODS: A Markov model was developed and adapted to
Colombian circumstances to evaluate the cost-effectiveness of
sunitinib vs. IFN-alfa. The model projected survival and costs in
6-week cycles based on extrapolation of the trial survival data.
The reference case analysis followed the patients until death or
for up to 1 year, however longer time horizons were considered
in the analysis (two, ﬁve, and ten years). Effectiveness was mea-
sured in terms of progression-free life years (PFLY), life-years
(LY) gained and quality adjusted life-years (QALY) gained.
Resource utilization and unit cost data were collected from: A
series of 15 patients with mRCC treated in Colombia, Colom-
bian expert clinical opinion and the cost of medication was
extracted from a Colombian Cancer reference institution (Liga
Colombiana de lucha contra el cáncer). Costs and beneﬁts were
discounted annually at 5%. All costs were calculated in 2006
Colombian pesos. Univariate sensitivity analyses was conducted.
RESULTS: For the reference case: the cost analysis suggested a
difference in favor of sunitinib of US$5711. The treatment with
sunitinib was associated with incremental gain in: PFLY of 0.23,
overall survival of 0.05 YL and QALY of 0.07. The incremental
cost-effectiveness ratio (ICER) and incremental cost-utility ratio
(ICUR) showed negative values, which indicated that sunitinib is
cost saving versus IFN-alfa. In the longer time horizon analysis
the sunitinib is dominant in the ﬁrst two years; for 5 and 10 years
analysis the ICER and the ICUR are around US$8200 and
US$6400 respectively. CONCLUSION: This analysis indicated
that sunitinib is a cost-effective treatment compared with IFN-
alfa as a ﬁrst-line treatment in mRCC in Colombia.
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OBJECTIVE: To investigate the economic impact of introducing
micafungin (MICA) for the treatment of systemic candida infec-
tions (SCIs) (including invasive candidiasis and candidaemia) in
the UK, a health economic analysis was performed comparing
MICA with liposomal amphotericin B (L-AMB). METHODS:
The model was based on data from a phase III, randomised,
double-blind trial which compared MICA with L-AMB. The
model period entails 14–20 weeks starting from initiation of
treatment and was analysed from a UK hospital perspective.
Hospitalisation and primary medication costs were included in
the current analysis. Unit costs of these resources were taken
from appropriate UK costing sources. As the price for MICA was
not available at the time of analysis, the price per recommended
daily dose (RDD) of MICA (100 mg) was assumed to be equal to
the price per RDD of caspofungin (50 mg). The model endpoint
was deﬁned as the percentage of patients that achieved complete
or partial clinical and mycological response after initial treat-
ment, and were alive after the 12-week follow-up period. The
model was analysed using cohort and second order Monte Carlo
(MC) simulation. RESULTS: The analysis shows that with MICA
52.9% of patients were successfully treated and survived 12
weeks after treatment ends compared to 49.1% for L-AMB.
MICA was also less expensive than L-AMB costing £26,838 and
£29,549 per patient, respectively. Because the costs are lower
and the effectiveness is higher for MICA (cost-effectiveness
[C/E] ratio = £50,755) in comparison with L-AMB (C/E
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ratio = £60,197), MICA dominates L-AMB. The results of the
MC simulation and the sensitivity analyses showed that MICA
remained the most cost-effective option. CONCLUSION: The
lower costs and higher effectiveness reported for MICA versus
L-AMB in this analysis indicate MICA is the more cost-effective
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OBJECTIVE: To estimate the cost-effectiveness of a national
immunization program against seasonal inﬂuenza targeting chil-
dren aged one to ﬁve years and adults aged 65+ years.
METHODS: Dynamic models simulate the indirect effect of vac-
cination conferred by herd protection, therefore, in order to
estimate the population effect of vaccination against inﬂuenza, a
transmission model comprising annual age classes was developed
to model the effects of age-speciﬁc infection, morbidity, and
mortality due to seasonal inﬂuenza. The structure of the
model followed the susceptible-latent-infected/morbid-recovered
schema for each age class. Transition between age classes was
modelled by either jumps to the next age class between inﬂuenza
seasons, or at a continuous rate. Assumptions concerning anti-
genic drift of the inﬂuenza strain were incorporated in the model
as the waning of vaccine-acquired immunity between successive
inﬂuenza seasons. Health beneﬁts were estimated using person-
years with inﬂuenza. Further developments are intended to
extend the outcome measures to include Quality-Adjusted Life
Years. Cost analysis was from a societal perspective in the
UK, however extension to other settings can be performed.
RESULTS: Assuming 60% vaccination coverage of the target
population in an inﬂuenza season, the ratio of person-years with
inﬂuenza to the initial population size is 0.99% for no vaccina-
tion and 0.85% with vaccination. This indicates that in the UK,
vaccination could prevent approximately 84,000 person-years of
inﬂuenza, which corresponds to 2,184,000 inﬂuenza episodes per
season, assuming infection lasts 2 weeks. The incremental cost
per person-year with inﬂuenza, with vaccination versus no vac-
cination was149. CONCLUSION: Initial results indicated that
the national immunization program targeting children aged 1–5
years and 65+ adults could be highly cost effective.
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OBJECTIVE: To estimate the CER of three health care delivery
models (HCDM) for HIV+ patients in Colombia. METHODS: A
review of 356 medical records from patients afﬁliated to institu-
tions under the Contributive Regimen in the Colombian Health
System was performed. The review incorporates data from 2002
to 2005, including disease status, treatment efﬁcacy, and costs of
care. VL and CD4 count data from the three-year analysis were
used as clinical outcomes. Direct costs included medications,
hospital expenses, doctor visits, laboratory tests, and other health
care providers costs. Description of the three models and analyses
of the services provided, teammembers, negotiations by planwere
described for each model. RESULTS: After controlling by disease
status and services utilization increase of CD4 count over the time
of the study was signiﬁcantly lower for patients in Model 3
(mean + 238 cells/mm3) than Model 1 (mean + 649 cells/mm3)
and Model 2 (mean + 676 cells/mm3). When VL was analyzed
patients in Model 1 had a higher decrease in VL levels -118,290
RNA copies vs. Model 2: -33,693 RNA copies and Model
3 = -33,504 RNA copies. Cost related to hospitalizations were
comparable in the threemodels and high differences were found in
the utilization and cost of outpatient services. However the overall
cost including antiretrovirals for patients in Model 1 was
$10,399.00, $11,617 forModel 2 and $11,002 forModel 3. After
a sensitivity analyses was performed CER were calculated. The
lower CER was $16.7 per CD4 cell/mm3 increased and $0.20 per
RNA copies decreased inModel 2 compared to $19 and $0.30 for
Model 1 and $26 and $0.58 for Model 3. CONCLUSIONS: Due
to differences in the plan characteristics and services utilization of
the Health Care Delivery Models, Model 2 appears to be a highly
cost-effective program relative to Model 1 and 3 health care
programs for HIV patients in Colombia.
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OBJECTIVE: Cytomegalovirus (CMV) remains the leading
opportunistic infection in the transplant population and is
responsible for numerous direct and indirect consequences. Some
clinical trials (Paya CV, et al. 2004; Ciancio G. et al. 2004) have
shown that prophylaxis with oral valganciclovir (VAL) is safe,
effective and less costly when compared with IV ganciclovir
(GAN) for the prevention of CMV infection in solid organ trans-
plant (SOT) recipients. Our aim was to compare costs and
medical resources of CMV infection prophylaxis in SOT recipi-
ents with oral VAL versus IV GAN in Brazil. METHODS: Based
on study of Paya CV, et al. 2004, we assumed the same efﬁcacy
for both oral VAL and IV GAN for the prevention of CMV
infection in SOT recipients. Therefore, a cost-minimization
analysis was developed to assess costs related to the prophylaxis
of CMV with oral VAL (900 mg/day) versus IV GAN (5 mg/kg/
day), under the payer’s perspective in Brazil. Only direct medical
costs (drugs, administration, physician fees and daily inpatient
care) were considered in this study. A panel with specialists was
conducted to reﬂect local practices. A 90-day timeframe was
considered based on the prophylaxis period which begins until
10 days after the transplant is done; consequently a discount rate
was not necessary. One-way sensitivity analyses were performed
to assess the robustness of the outcomes. RESULTS: Total costs
were R$17,673 for VAL and R$45,625, a savings of 61% per
patient. Cost-savings observed for VAL were due to lower costs
related to inpatient care (VAL: R$0 vs. GAN: R$29,520) and
lower administration costs (VAL: R$0 vs. GAN: R$7564). One-
way sensitivity analysis supported the robustness of the ﬁndings.
CONCLUSION: Findings suggest oral valganciclovir as a cost-
saving alternative for the prophylaxis of CMV infection in SOT
recipients under the payer perspective in Brazil.
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